GlassScriptPhysician profile
Lismore B Heron
NPI 1326047432
$3,542.41
in general payments reported to CMS, 2019-2025
24 companies · $404 in 2025
The $404 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $92.44 · 2020: $388 · 2021: $953 · 2022: $544 · 2023: $263 · 2024: $898 · 2025: $404.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,564.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,564.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $662.72 | 2019-2025 | |
| Abbott Laboratories | $450.45 | 2021-2024 | Thoratec Heartmate 3 Lvas Implant Kit, Aveir |
| Amgen INC. | $358.68 | 2021-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $353.25 | 2019-2024 | Xarelto |
| Pfizer INC. | $295.86 | 2020-2025 | |
| Sanofi-Aventis U.S. LLC | $288.45 | 2020-2023 | |
| E.R. Squibb & Sons, L.L.C. | $279.25 | 2020-2025 | Eliquis, Camzyos |
| Astrazeneca Pharmaceuticals LP | $152.27 | 2019-2021 | |
| Medtronic, INC. | $109.41 | 2024 | Micra |
| Kestra Medical Technology Services, INC. | $97.49 | 2024-2025 | Assure Wcd |
| Boston Scientific Corporation | $60.04 | 2023-2024 | Watchman Flx |
| Merck Sharp & Dohme LLC | $52.30 | 2021-2025 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.13 | 2022 | |
| Cvrx, INC. | $49.28 | 2024-2025 | Barostim Neo System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $47.95 | 2024-2025 | Lifevest |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $44.58 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $37.00 | 2024 | |
| Edwards Lifesciences Corporation | $27.34 | 2023 | |
| Novo Nordisk INC | $24.60 | 2024 | Wegovy |
| Kiniksa Pharmaceuticals International, Plc | $24.54 | 2024 | Arcalyst |
| Amarin Pharma, INC. | $22.64 | 2021 | |
| Astellas Pharma US INC | $19.30 | 2021 | |
| Atricure, INC. | $17.51 | 2024 | |
| Esperion Therapeutics, INC. | $15.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lismore Heron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.